Extensive-stage Small-cell Lung Cancer Clinical Trials

12 recruiting

Extensive-stage Small-cell Lung Cancer Trials at a Glance

12 actively recruiting trials for extensive-stage small-cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Shanghai, Zhengzhou, and Chengdu. Lead sponsors running extensive-stage small-cell lung cancer studies include Sichuan University, Henan Cancer Hospital, and European Organisation for Research and Treatment of Cancer - EORTC.

Browse extensive-stage small-cell lung cancer trials by phase

Treatments under study

About Extensive-stage Small-cell Lung Cancer Clinical Trials

Looking for clinical trials for Extensive-stage Small-cell Lung Cancer? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Extensive-stage Small-cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Extensive-stage Small-cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Extensive-stage Small-cell Lung Cancer
Second Hospital of Shanxi Medical University40 enrolled6 locationsNCT06536868
Recruiting
Phase 1

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Extensive-stage Small-cell Lung Cancer
Memorial Sloan Kettering Cancer Center24 enrolled7 locationsNCT06807632
Recruiting
Phase 3

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Extensive-stage Small-cell Lung Cancer
BioNTech SE621 enrolled138 locationsNCT06712355
Recruiting

Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC

Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital40 enrolled1 locationNCT07244016
Recruiting
Phase 2

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Liver MetastasesExtensive-stage Small-cell Lung Cancer
Kamya Sankar39 enrolled3 locationsNCT05588388
Recruiting
Phase 4

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Extensive-stage Small-cell Lung Cancer
Pharmacosmos A/S302 enrolled1 locationNCT05874401
Recruiting
Phase 2

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.66 enrolled1 locationNCT06437509
Recruiting
Phase 2

First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy

Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital47 enrolled1 locationNCT06586697
Recruiting
Phase 2

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

Extensive-stage Small-cell Lung Cancer
Sichuan University61 enrolled8 locationsNCT05765825
Recruiting
Phase 1Phase 2

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung CancerExtensive-stage Small-cell Lung Cancer
Sichuan University45 enrolled1 locationNCT06217757
Recruiting
Phase 2

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Extensive-stage Small-cell Lung Cancer
Universität des Saarlandes43 enrolled5 locationsNCT06223711
Recruiting
Not Applicable

PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)

Limited Stage Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC600 enrolled41 locationsNCT04790253